Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?

Emmanuel S. Antonarakis

doi:10.1016/S1470-2045(18)30409-1

Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	860-861
Number of pages	2
Journal	The Lancet Oncology
Volume	19
Issue number	7
DOIs	https://doi.org/10.1016/S1470-2045(18)30409-1
State	Published - Jul 2018
Externally published	Yes

Bibliographical note

Funding Information:
I am a paid consultant or advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis, and Merck. I have received research funding to my institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck. I am the co-inventor of a biomarker technology that has been licensed to Qiagen. This work was partially supported by the National Institutes of Health (P30 CA006973) and the US Department of Defense (W81XWH-16-PCRP-CCRSA).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/S1470-2045(18)30409-1

Find It

Find It at U of M Libraries

Cite this

@article{e30d0312c2ce4296b91ce1cd9aa0fc1f,

title = "Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?",

author = "Antonarakis, {Emmanuel S.}",

note = "Funding Information: I am a paid consultant or advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis, and Merck. I have received research funding to my institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck. I am the co-inventor of a biomarker technology that has been licensed to Qiagen. This work was partially supported by the National Institutes of Health (P30 CA006973) and the US Department of Defense (W81XWH-16-PCRP-CCRSA).",

year = "2018",

month = jul,

doi = "10.1016/S1470-2045(18)30409-1",

language = "English (US)",

volume = "19",

pages = "860--861",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "7",

}

TY - JOUR

T1 - Abiraterone plus olaparib in prostate cancer

T2 - a new form of synthetic lethality?

AU - Antonarakis, Emmanuel S.

N1 - Funding Information: I am a paid consultant or advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis, and Merck. I have received research funding to my institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck. I am the co-inventor of a biomarker technology that has been licensed to Qiagen. This work was partially supported by the National Institutes of Health (P30 CA006973) and the US Department of Defense (W81XWH-16-PCRP-CCRSA).

PY - 2018/7

Y1 - 2018/7

UR - http://www.scopus.com/inward/record.url?scp=85047857631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047857631&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30409-1

DO - 10.1016/S1470-2045(18)30409-1

M3 - Comment/debate

C2 - 29880290

AN - SCOPUS:85047857631

VL - 19

SP - 860

EP - 861

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -

Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Cite this